A carregar...
Dose Escalation and Dosimetry of First in Human Alpha Radioimmunotherapy with (212)Pb-TCMC-trastuzumab
Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity and tumor response of intraperitoneal (IP) (212)Pb-TCMC-trastuzumab (TCMC is S-2-(4-isothiocyantobenzl)-1, 4, 7, 10-tetraaza-1, 4, 7, 10=tetra (2-carbamoylmethl) cyclododecane) in patients with HER-2 expressing malig...
Na minha lista:
| Publicado no: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486012/ https://ncbi.nlm.nih.gov/pubmed/25157044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.114.143842 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|